NovoCare
Is NovoCare listed in FDA warning letters?
No FDA warning letters addressed to NovoCare appear in our dataset (FDA.gov letters 2023–2026). FDA has issued 2 warning letters to the manufacturer, Novo Nordisk Inc.: 2026-03-05, 2025-09-09. Subjects named in the FDA records: "Postmarketing Adverse Drug Experience Reporting Requirements" and "False & Misleading Claims/Misbranded".
Key facts
- •Care model: Manufacturer self-pay and access program.
- •Medications discussed: Wegovy (semaglutide), Wegovy Tablets (oral semaglutide), Saxenda (liraglutide).
- •State availability: Confirm directly with program. Note: The reviewed program page did not provide a state availability list. Confirm service and dispensing availability directly.
Manufacturer self-pay program for Wegovy. It is a way to fill a prescription, not a doctor-service plan.
- At a glance
- Care model
- Manufacturer self-pay program
- Medications discussed
- Wegovy (semaglutide), Wegovy Tablets (oral semaglutide), Saxenda (liraglutide)
- Availability
- Confirm with program
FDA Warning Letter Records Identified
NovoCare is the patient assistance and affordability portal operated by manufacturer Novo Nordisk Inc. Official FDA warning letters issued to the parent manufacturer concerning promotional materials and postmarketing reporting are detailed below.
Novo Nordisk Inc.
Center for Drug Evaluation and Research (CDER)
Subject: Postmarketing Adverse Drug Experience Reporting Requirements
FDA says nNI's written PADE procedures allowed rejection of serious unexpected ADEs based on reporter causality, invalidated cases lacking patient identifiers, and let cases stall in medical review, causing late or missed 15-day reports.
Novo Nordisk Inc.
Center for Drug Evaluation and Research (CDER)
Subject: False & Misleading Claims/Misbranded
FDA says a video titled "An Oprah Special: Shame, Blame, and the Weight Loss Revolution" omitted and minimized serious risks, including the boxed warning for thyroid C-cell tumors, misbranding Wegovy, Ozempic, and Victoza, and that the video was not submitted to FDA on Form FDA-2253 at initial publication.
Before you use this program
This is a manufacturer self-pay program for filling a prescription, not a care program. Read its terms on its own website.
- •Is a prescription from your own clinician required?
- •Which pharmacy fills the prescription, and how is it delivered?
- •Who do you contact with questions about an order?
Source records
Evaluate Eligibility & Coverage Before Enrolling in NovoCare
Check manufacturer copay card rules, federal program exclusions, and cash-pay vial terms for NovoCare.
Copay & Savings Card Rules
Model out-of-pocket copays for Zepbound and Wegovy under commercial plans ($25/mo caps) vs. self-pay cash channels.
Baseline Lab & Safety Screen
Legitimate telehealth prescribers require baseline kidney and A1c bloodwork. Review required panels and boxed warnings before your intake.
FDA BMI Indication Gauge
Verify whether your BMI meets official FDA prescribing standards (BMI ≥30 or ≥27 with comorbidity) before paying non-refundable fees.
Telehealth Navigation & Checklist
Evaluating a digital clinic? Review our clinical checklists for verifying state licensure, required blood work, and navigating insurance coverage.
How to Spot a Legit Clinic
Physician NPI checks, state licensing, and avoiding online scams.
How to Get a Prescription
Step-by-step telehealth workflow, required labs, and BMI criteria.
Prior Authorization Guide
Commercial insurance criteria, clinical documentation, and appeals.